Balchem Corporation scheduled a conference call for October 23, 2026, to discuss third-quarter financial results. CEO Ted Harris and CFO Martin Bengtsson will host the event, with financial data relea
Balchem Corporation announced that key executives, including CEO Ted Harris, will attend the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. The company specializes in developing and
Balchem Corporation reported strong Q2 2026 financial results, sparking debate over whether its stock is fully valued. With a P/E ratio of 34.3x exceeding the US Chemicals industry average, investors
Balchem Corporation reported strong Q2 2026 results with higher sales and net income, completing a $55.49 million share repurchase. Management confidence is evident, though risks regarding product inn
Balchem Corp, a chemicals company, reported Q2 2026 earnings with an 11.2% sales growth across all three segments. The update includes current stock performance and analyst ratings for investors.
Balchem released Q2 2026 results and a buyback update, with analysts estimating the stock is 16% undervalued driven by a new microencapsulation facility. High P/E ratios suggest potential valuation ri
Balchem Corp reported record consolidated sales of $284 million and adjusted EBITDA of $78 million for Q2 2026, driven by growth in Animal and Human Nutrition segments despite higher input costs.
Balchem Corporation reported Q2 2026 revenue of $284.0 million, an 11% increase driven by its Human Nutrition and Health segment. Adjusted earnings of $1.49 per share beat estimates, though the stock
Balchem Corporation reported strong Q2 2026 financial results, exceeding consensus estimates with $1.49 adjusted earnings per share and $284 million in revenue. Growth was driven by robust demand for
Balchem Corporation reported record Q2 fiscal 2026 financial results, with net sales increasing 11.2% year-over-year to $284.0 million. The company posted GAAP net earnings of $44.6 million and genera
Balchem Corporation reported record Q2 2026 net sales of $284.0 million, an 11.2% increase year-over-year. The company amended its credit agreement and repurchased $29 million in stock reflecting conf
Balchem Corporation reported second-quarter adjusted earnings per share of $1.49, exceeding analyst expectations of $1.40. The results indicate strong profitability for the specialty ingredients manuf
Balchem Corporation is scheduled to report Q2 2026 earnings on July 31, with analysts projecting EPS of $1.43 and revenue of $268.5 million. Market attention focuses on input cost and demand trends fo
Balchem Corporation is set to report second-quarter earnings with analysts anticipating a sequential decline, while investors monitor margin sustainability and segment performance in its nutrition bus
Balchem Corporation will release Q2FY26 financial results on July 31, 2026, followed by an investor conference call. The company specializes in specialty ingredients for human and animal nutrition and
ChemBrief